Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label phase 2 trial of Orca-T given to adults with acute myeloid leukemia (AML) in remission or to patients with myelodysplastic syndrome (MDS) who are eligible for reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) allogeneic hematopoietic cell transplantation (alloHCT). Orca-T is a donor-manufactured product composed of purified hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons) derived from an 8/8 HLA-matched related or unrelated donor. Participants receive the investigator-chosen RIC or NMA preparative regimen, Orca-T infusion from the matched donor, and single-agent graft-versus-host disease prophylaxis with tacrolimus. The trial further characterizes safety and tolerability and provides an initial look at efficacy in this lower-intensity transplant population, building on earlier phase 1 and ongoing phase 1b/3 experiences.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years at the time of enrollment
2. Diagnosed with 1 of the following diseases:

   1. Acute myeloid, or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), with or without the presence of known minimal residual disease.
   2. Myelodysplastic syndrome that is indicated for alloHCT per the 2017 International Expert Panel recommendations and/or therapy-related/secondary MDS as defined by the World Health Organization (WHO) classification of myeloid malignancies, with ≤10% blast burden in the bone marrow.
3. Planned to undergo 1 of the following preparative regimens as per Investigator discretion:

   1. RIC cohort: Planned RIC-alloHCT including RIC regimen with TBI/thiotepa/fludarabine
   2. NMA cohort: Planned NMA-alloHCT including NMA regimen with fludarabine/cyclophosphamide/TBI
4. Identified related or unrelated donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1
5. Estimated glomerular filtration rate ≥30 mL/minute
6. Cardiac ejection fraction at rest ≥40% or shortening fraction of ≥22% by echocardiogram or radionuclide scan (MUGA)
7. Diffusing capacity of the lung for carbon monoxide (adjusted for hemoglobin) ≥40%
8. Negative serum or urine β-HCG test in persons of childbearing potential
9. Alanine transaminase (ALT)/aspartate transaminase (AST) \<5 times the upper limit of normal (ULN)
10. Total bilirubin \<3 × ULN
11. Deemed ineligible for a fully myeloablative alloHCT per assessment of the principal investigator

Exclusion Criteria:

1. Prior alloHCT
2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
3. Planned donor lymphocyte infusion (DLI)
4. Planned pharmaceutical in vivo or ex vivo T-cell depletion
5. Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor
6. Karnofsky performance score \<60%
7. For RIC cohort only: HCT-Specific Comorbidity Index (HCT-CI) ≥6
8. Uncontrolled bacterial, viral, or fungal infection (currently taking antimicrobial therapy and with progression or no clinical improvement) at the time of enrollment
9. Seropositive for HIV-1 or -2, HTLV-1 or -2, hepatitis B surface antigen, or HCV antibody unless previously treated with curative therapy and are HCV NAT negative
10. Known allergy or hypersensitivity to or intolerance of tacrolimus
11. Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
12. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
13. Concurrent malignancy within 1 year except nonmelanoma skin cancer that has been curatively resected
14. Psychosocial circumstances that preclude the participant being able to go through transplantation or participate responsibly in follow-up care
15. Persons who are pregnant or breastfeeding
16. Person of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation.
17. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or medical monitor's judgment, precludes the recipient's safe participation in and completion of the trial or which could affect compliance with the protocol or interpretation of results

Where it's running

• UCLA Department of Medicine
  Los Angeles, California, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• John Theurer Cancer Center at Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting
• Weill Cornell Medicine - New York Presbyterian Hospital
  New York, New York, United States Recruiting
• Oregon Health and Science University
  Portland, Oregon, United States Recruiting
• Vanderbilt University, Ingram Cancer Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Chief Medical Officer
• Email: info@orcabio.com
• Phone: 650-246-9601

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Orca-T with myeloablative allogeneic stem cell transplant for advanced leukemias and MDS

  This Phase I study tests whether giving Orca-T alongside standard dual‑agent graft‑versus‑host disease prevention is safe in adults (18–70) receiving a myeloablative allogeneic stem cell transplant for acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06551584

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Testing Enzomenib for patients with relapsed or refractory acute leukemia

  This study is testing a new drug called Enzomenib to see if it can help adults with relapsed or hard-to-treat acute leukemia feel better.

  Recruiting at 80 sites Phase 1/2 Sumitomo Pharma America, Inc. · Newport Beach, California and 103 other locations · NCT04988555

• Evaluating Orca-Q in patients receiving stem cell transplants for blood cancers

  This study is testing a new type of donor graft called OrcaGraft to see if it can make stem cell transplants safer and more effective for people with blood cancers like leukemia.

  Recruiting at 9 sites Phase 1 Orca Biosystems, Inc. · Duarte, California and 11 other locations · NCT03802695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.